Figure S2

(A) *Nrf2*⁺⁺⁺

![Graph showing CD86 and CD40 expression levels under various conditions for Nrf2⁺⁺⁺.](image)

(B) *Nrf2*⁻⁻⁻

![Graph showing CD86 and CD40 expression levels under various conditions for Nrf2⁻⁻⁻.](image)

(C) LPS + DMF

<table>
<thead>
<tr>
<th></th>
<th>MED</th>
<th>0</th>
<th>10</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LPS + VEH

LPS + DMF 10

LPS + DMF 100
Figure S2.

Inflammatory activation of MG induced by LPS.

(A) The percentage of CD86$^+$ and CD40$^+$ cells in *Nrf2*$^{+/+}$ MG was measured in each treatment group. Data presented are from five independent experiments. ***p < 0.001 by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. MED, cell culture medium. (B) The percentage of CD86$^+$ and CD40$^+$ cells in *Nrf2*$^{-/-}$ MG was measured in each treatment group. Data presented are from three independent experiments. *p<0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA with Bonferroni’s post hoc multiple comparison test. (C) Representative western blot analysis shows that iNOS protein levels were upregulated by LPS (1 µg/ml) stimulation in MG. The cell lysates were prepared immediately following CM collected. DMF treatment suppressed iNOS protein induced by LPS stimulation in MG. Results are from three independent experiments.